Closely-held Soricimed Biopharma has announced the members of its newly formed Clinical Advisory Board (CAB).
The CAB, comprising key thought leaders in the treatment of cancer and novel anti-cancer targets, will provide Soricimed with ongoing expert strategic guidance on the continued clinical development of its lead anti-cancer drug candidate, SOR-C13, and its preclinical oncology pipeline.
The members of the CAB are Dr. Robert Coleman and Dr. Siqing Fu of MD Anderson Cancer Center, Dr. Manuel Hidalgo of Beth Israel Deaconess Medical Center and Harvard Medical School, Prof. Natacha Prevarskaya of Université des Sciences et Technologies de Lille and Dr. Stephen Welch of London Health Sciences Centre.
“We are honored to have these key opinion leaders join our CAB,” Paul Gunn, president and CEO, said in a statement. “Together, they bring a wealth of experience and expertise in our targeted cancer areas, such as pancreatic and ovarian cancer, as well as in clinical trial design and drug development. We look forward to their input as we take the next step in the clinical development of our anti-cancer peptide, SOR-C13.”
